SB
Samsara BioCapital Portfolio holdings
AUM
$489M
This Quarter Return
+31.17%
1 Year Return
+135.25%
3 Year Return
+909.96%
5 Year Return
+774.56%
10 Year Return
–
AUM
$570M
AUM Growth
+$570M
(+18%)
Cap. Flow
-$11.7M
Cap. Flow
% of AUM
-2.05%
Top 10 Holdings %
Top 10 Hldgs %
79.11%
Holding
57
New
1
Increased
1
Reduced
10
Closed
10
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$47.2M |
| 2 |
Lyra Therapeutics
LYRA
|
$4.12M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$14.9M |
| 2 |
Arcellx
ACLX
|
$9.35M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$7.35M |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$7.28M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$6.52M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $198M | 34.81% | 5,161,888 | – | – |
|
2
Mineralys Therapeutics
MLYS
$1.03B
| $77.1M | 13.52% | 4,519,361 | – | – |
|
|
SLRN
3
DELISTED
ACELYRIN
SLRN
| $47.2M | 8.28% | +2,256,022 | New | +$47.2M |
|
4
Scholar Rock
SRRK
$3.14B
| $34.7M | 6.09% | 4,598,828 | – | – |
|
|
LENZ
5
LENZ Therapeutics
LENZ
$1.1B
| $22M | 3.86% | 8,459,314 | – | – |
|
|
6
Arcellx
ACLX
$3.85B
| $19.4M | 3.41% | 613,921 -295,658 | -33% | -$9.35M |
|
|
AVDL
7
Avadel Pharmaceuticals
AVDL
$1.43B
| $15.9M | 2.8% | 967,527 -441,882 | -31% | -$7.28M |
|
8
Zymeworks
ZYME
$1.12B
| $12.6M | 2.21% | 1,458,875 -161,812 | -10% | -$1.4M |
|
|
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $12.1M | 2.13% | 308,151 -378,684 | -55% | -$14.9M |
|
|
10
Lyra Therapeutics
LYRA
$11.5M
| $11.4M | 2.01% | 2,780,261 +1,003,010 | +56% | +$4.12M |
|
11
HilleVax
HLVX
$105M
| $10.3M | 1.81% | 599,274 -10,588 | -2% | -$182K |
|
|
DICE
12
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $9.42M | 1.65% | 202,773 | – | – |
|
13
Sutro Biopharma
STRO
$72.7M
| $7.79M | 1.37% | 1,675,579 | – | – |
|
|
VRNA
14
Verona Pharma
VRNA
$9.16B
| $7.35M | 1.29% | 347,500 -347,501 | -50% | -$7.35M |
|
15
Aclaris Therapeutics
ACRS
$209M
| $7.22M | 1.27% | 696,171 | – | – |
|
|
ICPT
16
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $7.09M | 1.24% | 640,688 | – | – |
|
17
Prime Medicine
PRME
$578M
| $6.89M | 1.21% | 470,304 | – | – |
|
18
Nkarta
NKTX
$151M
| $6.28M | 1.1% | 2,868,035 | – | – |
|
19
PepGen
PEPG
$38M
| $5.82M | 1.02% | 651,050 | – | – |
|
20
Rhythm Pharmaceuticals
RYTM
$6.85B
| $5.69M | 1% | 345,293 | – | – |
|
21
Immunocore
IMCR
$1.62B
| $4.85M | 0.85% | 80,963 | – | – |
|
22
Immatics
IMTX
$619M
| $4.57M | 0.8% | 396,000 -99,000 | -20% | -$1.14M |
|
23
Janux Therapeutics
JANX
$1.37B
| $4.28M | 0.75% | 360,414 | – | – |
|
24
EyePoint Pharmaceuticals
EYPT
$797M
| $3.76M | 0.66% | 432,000 -48,000 | -10% | -$418K |
|
|
DBTX
25
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $3.09M | 0.54% | 801,629 | – | – |
|